Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The economic burden of glaucoma in the UK. The need for a far-sighted policy.

× No keyword cloud information.

9 in total

1. Cost-of-illness studies: a major headache?

Authors: M Drummond
Journal: Pharmacoeconomics Date: 1992-07 Impact factor: 4.981

2. Efficiency of referral for suspected glaucoma.

Authors: M W Tuck; R P Crick
Journal: BMJ Date: 1991-04-27

3. Priorities in biomedical research. Indices of burden.

Authors: D A Black; J D Pole
Journal: Br J Prev Soc Med Date: 1975-12

4. Incidence of manifest glaucoma.

Authors: B O Bengtsson
Journal: Br J Ophthalmol Date: 1989-07 Impact factor: 4.638

5. A year in a general ophthalmic outpatient department in England.

Authors: D E Shaw; J M Gibson; A R Rosenthal
Journal: Arch Ophthalmol Date: 1986-12

6. Bedford glaucoma survey.

Authors: J L Bankes; E S Perkins; S Tsolakis; J E Wright
Journal: Br Med J Date: 1968-03-30

7. Incidence estimates for lens changes, macular changes, open-angle glaucoma and diabetic retinopathy.

Authors: M J Podgor; M C Leske; F Ederer
Journal: Am J Epidemiol Date: 1983-08 Impact factor: 4.897

8. The prevalence of glaucoma.

Authors: B Bengtsson
Journal: Br J Ophthalmol Date: 1981-01 Impact factor: 4.638

9. Referral patterns to an ophthalmic outpatient clinic by general practitioners and ophthalmic opticians and the role of these professionals in screening for ocular disease.

Authors: R J Harrison; J M Wild; A J Hobley
Journal: BMJ Date: 1988-11-05

9 in total

8 in total

Review 1. Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension.

Authors: S S Patel; C M Spencer
Journal: Drugs Aging Date: 1996-11 Impact factor: 3.923

2. Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension.

Authors: W Y Zhang; A L Po; H S Dua; A Azuara-Blanco
Journal: Br J Ophthalmol Date: 2001-08 Impact factor: 4.638

Review 3. The economic burden of glaucoma and ocular hypertension: implications for patient management: a review.

Authors: Jean-François Rouland; Gilles Berdeaux; Antoine Lafuma
Journal: Drugs Aging Date: 2005 Impact factor: 3.923

4. Cost-minimisation study of dorzolamide versus brinzolamide in the treatment of ocular hypertension and primary open-angle glaucoma: in four European countries.

Authors: Jean-Francois Rouland; Claude Le Pen; Carlos Gouveia Pinto; Patrizia Berto; Gilles Berdeaux
Journal: Pharmacoeconomics Date: 2003 Impact factor: 4.981

5. Cost effectiveness of travoprost versus a fixed combination of latanoprost/timolol in patients with ocular hypertension or glaucoma: analysis based on the UK general practitioner research database.

Authors: Renato De Natale; Antoine Lafuma; Gilles Berdeaux
Journal: Clin Drug Investig Date: 2009 Impact factor: 2.859

Review 6. Bimatoprost: a pharmacoeconomic review of its use in open-angle glaucoma and ocular hypertension.

Authors: Greg L Plosker; Susan J Keam
Journal: Pharmacoeconomics Date: 2006 Impact factor: 4.981

7. Assessment of the cost effectiveness of travoprost versus latanoprost as single agents for treatment of glaucoma in France.

Authors: Stéphanie Payet; Philippe Denis; Gilles Berdeaux; Robert Launois
Journal: Clin Drug Investig Date: 2008 Impact factor: 2.859

8. Costs and persistence of alpha-2 adrenergic agonists versus carbonic anhydrase inhibitors, both associated with prostaglandin analogues, for glaucoma as recorded by The United Kingdom General Practitioner Research Database.

Authors: Philippe Denis; Antoine Lafuma; Gilles Berdeaux
Journal: Clin Ophthalmol Date: 2008-06

8 in total